Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Percheron Therapeutics ( (AU:PER) ) has shared an update.
Percheron Therapeutics Limited has released an updated corporate presentation providing new information on its HMBD-002 program and financial position. This update is significant as it highlights the company’s progress and future plans, particularly the commencement of further clinical trials in 2026, which could impact its operations and industry positioning.
The most recent analyst rating on (AU:PER) stock is a Buy with a A$0.24 price target. To see the full list of analyst forecasts on Percheron Therapeutics stock, see the AU:PER Stock Forecast page.
More about Percheron Therapeutics
Percheron Therapeutics Limited is a publicly listed biotechnology company focused on developing and commercializing novel therapies for oncology and rare diseases. The company’s lead program, HMBD-002, is a monoclonal antibody targeting the immune checkpoint regulator, VISTA, and has completed a phase I clinical trial showing it to be generally safe and well-tolerated.
Average Trading Volume: 2,086,546
Technical Sentiment Signal: Sell
Current Market Cap: A$10.87M
Find detailed analytics on PER stock on TipRanks’ Stock Analysis page.